We have shown previously that cytosolic phospholipase A # (cPLA # ) is responsible for endothelin-1-induced release of arachidonic acid for prostaglandin synthesis in cat iris sphincter smooth muscle (CISM) cells [Husain and Abdel-Latif (1998) Biochim. Biophys. Acta 1392, 127-144]. Here we show that p38 mitogen-activated protein (MAP) kinase, but not p42\p44 MAP kinases, plays an important role in the phosphorylation and activation of cPLA # in endothelin-1-stimulated CISM cells. This conclusion is supported by the following findings. Both p38 MAP kinase and p42\p44 MAP kinases were present in the CISM cells and both were activated by endothelin-1. SB203580, a potent specific inhibitor of p38 MAP kinase, but not the p42\p44 MAP kinases specific inhibitor, PD98059, markedly suppressed endothelin-1-enhanced cPLA # phosphorylation, cPLA # activity and arachidonic acid release. The addition of endothelin-1 resulted in the phosphorylation and activation of cPLA # . Endothelin-1 stimulated p38 MAP kinase activity in a time-and concentration-dependent manner, and these effects were mediated through the endothelin-A receptor subtype. The protein kinase C (PKC) inhibitor, RO 31-8220, had no inhibitory effect on endothelin-1-induced p38 MAP kinase activation,
INTRODUCTION
The endothelins are a family of three peptides, termed endothelin-1, endothelin-2 and endothelin-3, that have a variety of biological effects including contraction of smooth muscle, cardiac inotropism, modulation of other hormones and cytokine production, regulation of transport in the renal tubule, regulation of intraocular pressure in the eye, and stimulation of mitogenesis (reviewed in [1, 2] ). In general, endothelins trigger their actions by activating specific cell-surface receptors that belong to the heptahelical G-protein-coupled superfamily of receptors. In mammalian tissues, two major endothelin receptors have been identified, namely endothelin A and endothelin B [1, 2] . In smooth muscle, the endothelin-A receptor is coupled to the activation of phospholipases A # , C and D and protein kinases, and to muscle contraction [1] [2] [3] [4] . In iris sphincter smooth muscle, endothelin-1 is a potent agonist for phosphoinositide hydrolysis and contraction [5] , and furthermore, in this tissue, the peptide induces arachidonic acid release, through activation of phospholipase A # , for prostaglandin synthesis [6] , and phosphatidic acid via activation of phospholipase D [7] .
There is accumulating experimental evidence which indicates that in a wide variety of tissues, the key enzyme responsible for suggesting that endothelin-1 activation of p38 MAP kinase is independent of PKC. Pertussis toxin inhibited both endothelin-1 and mastoparan stimulation of p38 MAP kinase activity and arachidonic acid release. The inhibitory effects of pertussis toxin are not mediated through cAMP formation. Mastoparanstimulated [$H]arachidonic acid release and cPLA # activation was inhibited by SB203580, but not by . These data suggest that endothelin-1 binds to the endothelin-A receptor to activate the Gi-protein which, through a series of kinases, leads to the activation of p38 MAP kinase and subsequently to phosphorylation and activation of cPLA # . Activation of cPLA # leads to the liberation of arachidonic acid from membrane phospholipids. The ability of the activated endothelin-A receptor, which is coupled to both Gq-and Gi-proteins, to recruit and activate this complex signal transduction pathway remains to be elucidated. Further studies on the mechanism of these relationships could provide important information about the functions of p38 MAP kinase in smooth muscle.
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agonist-induced arachidonic acid release is cytosolic phospholipase A # (cPLA # ) [8] [9] [10] . The activity of cPLA # is regulated by an increase in intracellular Ca# + concentration and by phosphorylation. Phorbol esters, activators of protein kinase C (PKC) and the calcium ionophores, A23187 and ionomycin, have been shown to increase arachidonic acid release and prostaglandin synthesis in a wide variety of isolated cells [11] [12] [13] , suggesting a role for PKC in cPLA # activation. More recent studies designed to identify protein kinases other than PKC that could be involved in phosphorylation and activation of the 85 kDa cPLA # have implicated a role for mitogen-activated protein (MAP) kinases [13, 14] . Concomitant activation of p42\p44 MAP kinases and cPLA # is observed in many cells [14] . Vascular endothelial growth factor stimulates prostacyclin production and activation of cPLA # in endothelial cells via p42\p44 MAP kinases [15] . However, thrombin caused cPLA # phosphorylation in human platelets without a concomitant stimulation of p42\p44 MAP kinases [16, 17] . In contrast, phosphorylation and activation of cPLA # by p38 MAP kinase has been observed in collagen- [18] and thrombin- [19] stimulated human platelets. Phosphorylation and activation of cPLA # in human neutrophils treated with tumour necrosis factor-α is regulated by p38 MAP kinase rather than by p42\p44 MAP kinases [20] .
There is little known about the role and regulation of cPLA # in agonist-induced arachidonic acid release in smooth muscle. We reported previously that endothelin-1 markedly increases arachidonic acid liberation in cat iris sphincter smooth muscle (CISM) cells and that PKCα and cPLA # play an important role in the mechanism of endothelin-1-induced arachidonic acid release [21] . The purpose of the present study was to determine the role of MAP kinases in endothelin-1-induced arachidonic acid release in these cells. The results obtained show that in CISM cells treated with endothelin-1, p38 MAP kinase, but not p42\p44 MAP kinases, is involved in phosphorylation and activation of cPLA # , and that both p38 MAP kinase and cPLA # are regulated by Gi-proteins.
MATERIALS AND METHODS

Materials
Polyclonal anti-(MAP kinase R2) antibodies (Erk1-CT), recognizing p42, p43 and p44 MAP kinases were purchased from Upstate Biotechnology (Lake Placid, NY, U.S.A. 
Cell culture
Iris sphincter smooth muscle cells were isolated from 4-6 month old cats as described previously [21] . Briefly, the eyes were enucleated immediately after the death of the animal and sphincter muscle was dissected out, further cleaned and cut into 1-2 mm# pieces. The explants were placed in Dulbecco's modified Eagle's medium (DMEM) containing 2 mg\ml collagenase type IA, 10 % (v\v) fetal bovine serum and 50 µg\ml gentamicin, and then incubated for 1-2 h at 37 mC with occasional gentle shaking. The cell suspension was centrifuged at 200 g and resuspended in DMEM\F-12 supplemented with 10 % (v\v) fetal bovine serum and 100 units\ml penicillin, 100 µg\ml streptomycin and 0.25 µg\ml amphotericin B in 5 % CO # humidified atmosphere. The contaminating fibroblasts were removed as described previously [21] . After 3 days, one-third of the culture medium was replaced with fresh medium. The smooth muscle cells were subcultured at a split ratio of 1 : 3 using 0.05 % trypsin and 0.02 % EDTA.
Measurement of [ 3 H]arachidonic acid release
CISM cells (passages 3-10) were grown to confluence in 12 well plates and incubated with 0.75 µCi\ml [$H]arachidonic acid for 24 h at 37 mC in DMEM containing 0.1 mg\ml BSA. After labelling, the cells were washed three times with non-radioactive DMEM to remove unincorporated arachidonic acid and then incubated in the absence or presence of the agonists in 1 ml of serum-free DMEM, as described previously [21] . In experiments where inhibitors were employed, the cells were preincubated with the inhibitor for the indicated time prior to addition of the agonist. At the end of incubation, the medium was centrifuged at 1400 g for 10 min at 4 mC, and the radioactivity in the supernatant determined by liquid scintillation spectrometry. Alternatively, the medium was acidified with 10 % (v\v) formic acid to pH 3.5 and extracted three times with 3 ml of ethyl acetate. The solvent was evaporated under N # . The residue was dissolved in chloroform\methanol (2 : 1, v\v), spotted on Whatman precoated silica gel LK6DF plates and developed in the organic phase of a solvent system of ethyl acetate\acetic acid\trimethyl pentane\ water (11 : 2 : 5 : 10, by vol.) as described previously [6] . After the bands were made visible using I # vapor, the radioactive content of arachidonic acid was measured by counting in a Beckman liquid-scintillation counter. Comparable amounts of radioactivity were obtained before and after extraction.
SDS/PAGE and immunoblotting
CISM cells were lysed in 50 mM Tris\HCl, pH 8.0, containing 100 mM NaCl, 1 mM EDTA, 1 % (v\v) Nonidet P-40, 0.1 % SDS, 0.5 % deoxycholate, 50 mM NaF, 1 mM Na $ VO % , 5 mM PMSF, 10 µg\ml leupeptin and 50 µg\ml aprotinin, for 20 min on ice. Cell lysates were centrifuged at 2500 g for 10 min and the supernatant was used for immuno-detection of cPLA # , p38 MAP kinase, and p42\p44 MAP kinases. Equal amounts of proteins were then resolved by SDS\PAGE [10 % (w\v) gel]. Prestained Kaleidoscope (range 7.1-208 kDa) and SDS\PAGE (low range 20.5-112 kDa) standards were run in parallel as protein molecular mass markers.
Proteins were then transferred to nitrocellulose membranes and probed with antibodies specific to cPLA # , p42\p44 MAPkinases and p38 MAP kinase, followed by an incubation with secondary antibodies (horse radish peroxidase conjugated goat anti-rabbit IgG at 1 : 3000 dilution) for 1 h at 20 mC as described previously [21] . For chemiluminescent detection, the membranes were treated with enhanced chemiluminescent (ECL 2 ) reagent (Amersham) for 1 min and subsequently exposed to ECL 2 hyperfilm for 1-2 min.
Labelling of cells with [
32 P]P i and immunoprecipitation of 32 Plabelled cPLA 2 CISM cells were grown in 25 cm# flasks to confluence and starved for 24 h in serum-free medium. Prior to labelling with [$#P]P i the cells were preincubated in phosphate-free medium for 30 min at 37 mC. The cells were incubated for 6 h in 3 ml of phosphate-free DMEM containing carrier-free [$#P]P i (100 µCi\ml) and then incubated in the absence or presence of 100 nM endothelin-1 for 5 min. The inhibitors were added 15 min prior to the addition of the agonist. The labelled cells were first washed with ice-cold PBS (Ca# + \Mg# + free), lysed in 1 ml of lysis buffer containing 50 mM Tris\HCl, pH 7.5, 1 % (v\v) Triton X-100, 0.5 % deoxycholate, 10 mM EDTA, 1 mM PMSF, 10 mM sodium pyrophosphate, 50 mM NaF, 200 µM Na $ VO % , 10 µg\ml leupeptin and 50 µg\ml aprotinin, then placed on ice for 30 min and sonicated. The cytosolic fraction was obtained by centrifugation at 100 000 g, as described previously [22] , and p38 mitogen-activated protein kinase and cytosolic phospholipase A 2 in smooth muscle cPLA # was isolated by immunoprecipitation using rabbit anti-cPLA # polyclonal antibodies for 2 h, followed by an incubation for 1 h with Protein A-Sepharose as described previously [21] . The immunoprecipitates were washed and extracted with Laemmli buffer [0.5 M Tris\HCl, pH 6.8, 10 % (v\v) glycerol, 5 % (v\v) β-mercaptoethanol, 10 % (w\v) SDS, Bromophenol Blue] for 15 min at 60 mC and resolved by SDS\PAGE (10 % gel) [23] . The gels were dried and exposed to Amersham Hyperfilm at k70 mC and phosphorylation was quantified by densitometry as described previously [22] .
Measurement of p42/p44 MAP kinase activation in CISM cells
MAP kinase activity was characterized by the in situ MBP phosphorylation assay adapted from Kameshita and Fujisawa [24] . Briefly, quiescent cells were stimulated with 100 nM endothelin-1 and scraped into ice-cold extraction buffer (20 mM β-glycerophosphate, 20 mM NaF, 2 mM EDTA, 0.2 mM Na $ VO % , 1 mM PMSF, 25 µg\ml leupeptin, 10 µg\ml aprotinin, and 0.3 % β-mercaptoethanol, pH 7.5). The inhibitors were added 15 min prior to the addition of the agonist. The cell extracts were centrifuged at 10 000 g for 10 min at 4 mC and the supernatant was resolved by SDS\PAGE (10 % polyacrylamide gel co-polymerized with 0.5 mg\ml MBP). After electrophoresis, the gels were washed with 50 mM Tris\HCl, pH 8.0, containing 20 % (v\v) propanol to remove the SDS, then washed with denaturing buffer (50 mM Tris\HCl, pH 8.0, 6 M guanidine hydrochloride, 5 mM β-mercaptoethanol). The enzymes on the gel were then renatured by washing with 50 mM Tris\HCl, pH 8.0, containing 0.04 % (v\v) Tween-40 and 5 mM β-mercaptoethanol at 4 mC for 21 h. The gel was then preincubated with assay buffer containing 40 mM Hepes, pH 8.0, 10 mM MgCl # , 2 mM dithiothreitol and 0.1 mM EGTA at 30 mC for 30 min. The MAP kinase activity was determined by incubating the gel with 20 ml of the assay buffer, which contained 20 µM ATP and 100 µCi [γ-$#P]ATP, at 30 mC for 1 h. After extensive washing in 5 % (w\v) trichloroacetic acid containing 10 mM sodium pyrophosphate, the gel was dried and autoradiographed at k70 mC.
p38 MAP kinase assay
CISM cells were starved for 18 h, incubated in the absence or presence of agonist at 37 mC for the indicated time intervals and then lysed in 20 mM Hepes buffer, pH 7.5, containing 3 mM MgCl # , 100 mM NaCl, 1 mM dithiothreitol, 1 mM PMSF, 10 µg\ml leupeptin, 10 µg\ml aprotinin, 1 mM EGTA, 1 mM Na $ VO % , 10 mM NaF, 20 mM β-glycerophosphate and 0.5 % Nonidet P-40, on ice. The lysate was centrifuged at 10 000 g for 10 min at 4 mC. The p38 MAP kinase was immunoprecipitated with anti-(p38 MAP kinase) polyclonal antibodies followed by the addition of Protein A-Sepharose for 12 h at 4 mC with mild shaking [25] . The immunoprecipitates were washed with the kinase reaction buffer (20 mM Hepes buffer, 10 mM MgCl # , 0.1 mM PMSF, 5 µg\ml aprotinin, 5 µg\ml leupeptin, 0.1 mM EGTA, 0.2 mM Na $ VO % , 0.5 mM β-glycerophosphate). The washed immunoprecipitates were incubated in 30 µl of reaction buffer containing 1 µg of affinity purified glutathione Stransferase-activating transcription factor-2 (GST-ATF2 ; amino acids 1-505) and 2.5 µCi of [γ-$#P]ATP at 30 mC for 15 min. The reaction was stopped by adding 4i Laemmli buffer. The samples were separated by SDS\PAGE (10 % gel) and the radioactivity incorporated into ATF2 was measured by autoradiography.
Phospholipase A 2 assay
Cells grown in 25 cm# flasks were starved for 18 h, incubated in the presence or absence of the agonists as indicated, then lysed in 50 mM Hepes buffer, pH 7.4, containing 350 mM sucrose, 1 mM EGTA, 10 µg\ml PMSF, 10 µg\ml leupeptin, 10 µg\ml aprotinin, 200 µM Na $ VO % and 50 mM NaF. PLA # activity in the 100 000 g cytosolic fraction of CISM cells (50-100 µg of protein\ assay) was measured using -3-phosphatidylcholine 1-stearoyl-2-["%C]arachidonyl as substrate [21] . Briefly, 11 µl of radiolabelled phospholipid was dried under N # , added to 0.5 ml of reaction mixture (25 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM CaCl # , 1 mM dithiothreitol, 1 mg\ml BSA) and then sonicated on ice. The reaction mixture (50 µl) containing 25 µg of protein was incubated at 37 mC for 30 min. The reaction was stopped by adding 2.5 ml of Dole's reagent (2-propanol\heptane\0.5 M H # SO % , 20 : 5 : 1, by vol.), 1.5 ml of heptane, 1 ml of water and mixed thoroughly. The heptane phase containing radioactive fatty acid was passed through a silicic acid chromatography column. The eluates were collected and radioactivity was measured by liquid scintillation spectrometry.
Assay of cAMP
CISM cells were preincubated with 0.1 mM 3-isobutyl-1-methylxanthine for 10 min and treated with different agonists for the indicated time interval. The incubations were stopped by the addition of 1.0 ml of 10 % (w\v) trichloroacetic acid. After appropriate dilutions of the supernatant, cAMP in the sample was succinylated and assayed by radioimmunoassay according to the procedure of Frandsen and Krishna [26] .
Figure 1 (A) Immunochemical identification of p38 MAP kinase and (B) activation of p38 MAP kinase by endothelin-1 in CISM cells
(A) Left lane, cell lysate (10-15 µg protein) was analysed by SDS/PAGE (10 % gel) and immunoblotted with polyclonal antibody specific to p38 MAP kinase as described in the Materials and methods section. Right lane, 3T3 cell extract was used as a positive control. (B) Cells were incubated in the presence and absence (control) of endothelin-1 (100 nM) for 5 min and p38 MAP kinase was immunoprecipitated from cell lysate by polyclonal anti-(p38 MAP kinase) antibodies. Activity of p38 MAP kinase was measured in the immunoprecipitates using [γ- 32 P]ATP and ATF2 as substrates. Phosphorylated ATF2 was detected after SDS/PAGE by autoradiography as described in the Materials and methods section. ET, endothelin.
Figure 2 Effects of different concentrations of endothelin-1 on p38 MAP kinase activity
CISM cells were starved for 18 h and incubated in the absence and presence of different concentrations of endothelin-1 as indicated for 5 min. The p38 MAP kinase activity was measured in the immunoprecipitates using [γ-
32 P]ATP and ATF2 for 15 min at 30 mC as described in the Materials and methods section. Supernatants were spotted on to P81 phosphocellulose paper, and 32 P incorporation into ATF2 was determined by scintillation counting. The results are expressed as a percentage of the control (without endothelin-1). Results are meanspS.E.M. for six determinations from two experiments.
RESULTS
Immunochemical identification and activation of p38 MAP kinase by endothelin-1 in CISM cells
We examined the presence of p38 MAP kinase in CISM cells by using polyclonal antibodies specific for p38 MAP kinase. As shown in Figure 1 (A), antibodies directed against p38 MAP kinase revealed an immunoreactive band (lane 1) indicating the presence of p38 MAP kinase. The p38 MAP kinase band was also detected in 3T3 cell lysate which was used as a positive control ( Figure 1A, lane 2) . To test the specificity of the anti-(p38 MAP kinase) IgG, p38 MAP kinase immunoprecipitates were applied next to p42\p44 MAP kinases immunoprecipitates on SDS\10 % polyacrylamide gels. A clear difference in the electrophoretic mobility of the two kinases was observed (results not shown). The effect of endothelin-1 on p38 MAP kinase activity is given in Figure 1(B) . The peptide induced a robust activation of p38 MAP kinase when ATF2 was used as substrate. We have reported previously that both p42\p44 MAP kinases are activated by endothelin-1 in these cells [21] . The PKC inhibitor, RO 31-8220, had no inhibitory effect on endothelin-1-induced p38 MAP kinase activation, suggesting that endothelin-1 activation of p38 MAP kinase is independent of PKC (results not shown). These data demonstrate the presence of p38 MAP kinase in the CISM cells and its activation by endothelin-1.
Effects of different concentrations of endothelin-1 on p38 MAP kinase activity
Endothelin-1 increased p38 MAP kinase activity in a concentration-dependent manner with an EC &! value of 8i10 −* M (Figure 2) . A significant increase in p38 MAP kinase activity was observed at 1 nM endothelin-1. Increasing concentrations of the agonist provoked a corresponding increase in the kinase activity, reaching a maximum at 100 nM. All subsequent experiments were performed employing 100 nM endothelin-1.
Figure 3 Time course of endothelin-1-stimulation of p38 MAP kinase activity
CISM cells were starved for 18 h and incubated with 100 nM endothelin-1 for the time intervals indicated. After incubation, p38 kinase activity was measured as described in Figure 2 . The data are meanspS.E.M. for six determinations from two experiments.
Time course of endothelin-1-stimulation of p38 MAP kinase activity
Endothelin-1 increased p38 MAP kinase activity in a timedependent manner with a t "/# (effective time for half maximal response) value of 3.0 min (Figure 3 ). After 2.5 min of incubation with endothelin-1, p38 MAP kinase activity was increased by 80 % and after 5 min it was increased by 226 %. All subsequent experiments were performed using a 5 min incubation. 
Effects of endothelin-A and endothelin-B receptor antagonists on
Inhibition of endothelin-1-induced cPLA 2 phosphorylation by the p38 MAP kinase inhibitor SB203580
To determine whether cPLA # is a physiological substrate for p38 MAP kinase in endothelin-1-stimulated cells, we employed the pyridinyl imidazole, SB203580, a specific inhibitor of p38 MAP kinase [18, 27] . As shown in Figure 4 (A), endothelin-1-induced phosphorylation of cPLA # was markedly inhibited by SB203580. Figure 4(B) shows the presence of the same amount of cPLA # in all the samples. To compare the values in the absence and presence of the inhibitor, the extent of phosphorylation was quantified by densitometry. As shown in Figure 4 (C), endothelin-1-induced cPLA # phosphorylation was inhibited by 47 % in the p38 mitogen-activated protein kinase and cytosolic phospholipase A 2 in smooth muscle 
Figure 4 Inhibition of endothelin-1-induced cPLA 2 phosphorylation by SB203580
(A) Phosphorylation of cPLA 2 . CISM cells were labelled with [ 32 P]P i for 6 h then incubated in the presence and absence of SB203580 (1 µM) or PD98059 (1 µM) as indicated for 15 min. The cellswere then stimulatedwithendothelin-1 (100 nM)for 5 minandcPLA 2 wasimmunoprecipitated from the 100 000 g cytosolic fraction by polyclonal antibodies specific for cPLA 2 and separated by SDS/PAGE. The radioactive bands were detected by autoradiography. Lane 1, control ; lane 2, 100 nM endothelin-1 ; lane 3, 100 nM endothelin-1j1 µM SB203580 ; lane 4, 100 nM endothelin-1j1 µM PD98059. (B) Western blot analysis of the immunoprecipitated cPLA 2 . After autoradiography, the nitrocellulose membrane was used for cPLA 2 detection by Western blot analysis using anti-cPLA 2 polyclonal antibodies as described in the Materials and methods section. (C) Quantification of cPLA 2 phosphorylation. cPLA 2 phosphorylation in CISM cells was quantified by densitometry. The autoradiographs were quantified by scanning with an UltraScan XL-enhanced laser densitometer. Results are from one experiment which is a representative of three independent experiments. presence of SB203580. The results provide direct evidence that p38 MAP kinase is responsible for cPLA # phosphorylation in the endothelin-1-stimulated cells. In contrast to the inhibitory effects of SB203580, PD98059, a specific inhibitor of p42\p44 MAP kinases, had no inhibitory effect on endothelin-1-induced cPLA # phosphorylation ( Figures 4A and 4C ). These results demonstrate that p38 MAP kinase, but not p42\p44 MAP kinases, is involved in phosphorylation of cPLA # in endothelin-1-stimulated smooth muscle cells. The confluent cells were prelabelled with [ 3 H]arachidonic acid in serum-free DMEM in the presence of 0.1 mg/ml BSA. The cells were incubated in the presence and absence of different concentrations of SB203580 for 15 min. Endothelin-1 (100 nM) was added for 5 min and then the release of [ 3 H]arachidonic acid into the medium was determined as described in the Materials and methods section. Data are the meanspS.E.M. for triplicate determinations from a single experiment that is a representative of six separate experiments. AA, arachidonic acid.
Effects of SB203580 and PD98059 on endothelin-1-induced p38 MAP kinase activation and [ 3 H]arachidonic acid release
We reported previously that phosphorylation of cPLA # is critical for endothelin-1-stimulation of arachidonic acid release in CISM cells [21] . Since inhibition of p38 MAP kinase blocked endothelin-1-induced cPLA # phosphorylation ( Figure 4 ) it was of interest to determine whether this inhibition also blocks endothelin-1 stimulation of arachidonic acid release. As shown in Figure 5 , addition of SB203580 inhibited endothelin-1-induced [$H]arachidonic acid release in a concentration-dependent manner with an IC &! value of 1i10 −( M. Endothelin-1-induced arachidonic acid release was inhibited by 50 % in the presence of 0.1 µM SB203580 and higher concentrations of the inhibitor did not enhance the inhibition ( Figure 5 ). In contrast, PD98059, a p42\p44 MAP kinases inhibitor, had no inhibitory effect on endothelin-1-induced arachidonic acid release ( Figure 6A ), although it blocked completely endothelin-1-stimulation of these kinases ( Figure 6B ). We have reported earlier that greater than 80 % of the radioactive
Figure 6 Effects of PD98059 on endothelin-1-induced (A) [ 3 H]arachidonic acid release and (B) p42/p44 MAP-kinases activity (A) CISM cells were labelled with [
3 H]arachidonic acid as described in Figure 5 then pretreated with PD98059 (1 µM) for 15 min, followed by an incubation with endothelin-1 (100 nM) for 5 min. After the incubation, [ 3 H]arachidonic acid release into the medium was determined as described in the Materials and methods section. The data are meanspS.E.M. for triplicate determinations from one experiment which is representative of four separate experiments. (B) CISM cells were preincubated with PD98059 (1 µM) for 15 min followed by the addition of endothelin-1 (100 nM) for 5 min. The cell lysates were then subjected to electrophoresis on SDS/PAGE containing 0.5 mg/ml MBP. Proteins resolved on the gel were denatured and renatured, as described in the Materials and methods section, and then incubated with 20 µM ATP and 100 µCi [γ-32 P]ATP in the kinase assay buffer at 30 mC for 1 h. After drying the gel, the phosphorylated bands were made visible by autoradiography. Results shown are representative of three separate experiments.
counts released into the medium were associated with the arachidonic acid fraction, the remaining 20 % of the counts were cyclooxygenase products and other unidentified metabolites [21] . These results demonstrate the involvement of p38 MAP kinase, but not p42\p44 MAP kinases, in endothelin-1-induced arachidonic acid release in CISM cells.
Effects of SB203580 and PD98059 on endothelin-1-induced cPLA 2 activity
We reported previously that phosphorylation of cPLA # is necessary for its catalytic activity and for endothelin-1-induced arachidonic acid release [21] . To investigate the relationship between p38 MAP kinase and cPLA # activation, the smooth muscle cells were preincubated with either SB203580 or PD98059, followed by the addition of endothelin-1 and measurement of cPLA # activity in the 100 000 g cytosolic fraction. As shown in Table 2 , endothelin-1 increased cPLA # activity by 86 % and this was 
Figure 7 Effects of pertussis toxin (PTX) treatment on (A) endothelin-1-stimulated [ 3 H]arachidonic acid release, (B) endothelin-1-induced p38 MAP kinase activity and (C) Western blot analysis of p38 MAP kinase immunoprecipitates
(A) Confluent CISM cells were prelabelled with [ 3 H]arachidonic acid ([ 3 H]AA) as described in Figure 5 . The cells were then incubated in the presence and absence of pertussis toxin (500 ng/ml) for 1 h, followed by treatment with endothelin-1 for 5 min. After incubation with endothelin-1, [
3 H]arachidonic acid release into the medium was determined as described in the Materials and methods section. The data are meanspS.E.M. for triplicate determinations from a single experiment that is a representative of four experiments. (B) Confluent CISM cells were starved for 18 h, pretreated with pertussis toxin (500 ng/ml) for 1 h, followed by the addition of endothelin-1 for 5 min. p38 MAP kinase activity in the immunoprecipitates was determined as described in Figure 1(B) . (C) Equal amounts of immunoprecipitates were separated by SDS/PAGE and the proteins were transferred to a nitrocellulose membrane. The membrane was probed with polyclonal antibodies specific for p38 MAP kinase as described in the Materials and methods section. Results shown are from one experiment that is representative of four separate experiments. p38 mitogen-activated protein kinase and cytosolic phospholipase A 2 in smooth muscle
Figure 8 Effects of SB203580 and pertussis toxin treatment on (A) endothelin-1-stimulated [ 3 H]arachidonic acid release, (B) endothelin-1-stimulated p38 MAP kinase activity, (C) quantification of p38 MAP kinase and (D) Western blot analysis of p38 MAP kinase immunoprecipitates (A) Confluent cells were prelabelled with [
3 H]arachidonic acid as described in Figure 5 . The cells were then treated in the absence or presence of pertussis toxin (500 ng/ml) for 1 h, followed by treatment with endothelin-1 for 5 min. In the case of SB203580, cells were pretreated with the inhibitor for 15 min prior to endothelin-1 treatment. After incubation, [ 3 H]arachidonic acid release into the medium was determined as described in the Materials and methods section. Results are meanspS.E.M. for three determinations from one representative experiment. (B) Confluent CISM cells were starved for 18 h, then treated as described above. p38 MAP kinase activity in the immunoprecipitates was determined as described in Figure 1(B) . Results are from one experiment that is representative of three different experiments. (C) MAP kinase phosphorylation was quantified by densitometry as described in Figure 4 (C). (D) p38 MAP kinase was detected using p38 MAP kinase specific polyclonal antibodies as described in Figure 7 (C).
completely inhibited by SB203580, but not by PD98059. These results suggest involvement of p38 MAP kinase in cPLA # phosphorylation and activation.
Figure9 Effectsofpertussistoxin(PTX)treatmenton(A)mastoparan-induced [ 3 H]arachidonic acid release, (B) mastoparan-stimulated p38 MAP activity and (C) Western blot analysis of p38 MAP kinase immunoprecipitates
Experimental conditions were the same as described in Figure 7 except that endothelin-1 was replaced by mastoparan (Mast, 10 µM) and the time of incubation with this agonist was for 15 min.
Involvement of pertussis toxin-sensitive G-proteins in p38 MAP kinase activation and [ 3 H]arachidonic acid release
The involvement of G-proteins in endothelin-1-induced arachidonic acid release in CISM cells was addressed by pretreatment of the cells with pertussis toxin. As shown in Figure 7 , endothelin-1-stimulated [$H]arachidonic acid release was reduced by pertussis toxin treatment by about 51 % ( Figure 7A ). The toxin also induced partial inhibition of endothelin-1-induced p38 MAP kinase activation ( Figure 7B ). Equal amounts of p38 MAP kinase were immunoprecipitated from all the samples ( Figure  7C ). These results suggest involvement of a pertussis toxinsensitive Gi-protein in endothelin-1-activation of p38 MAP kinase and endothelin-1-induced [$H]arachidonic acid release in these cells.
Effects of SB203580 and pertussis toxin treatment on endothelin-1-stimulated [ 3 H]arachidonic acid release and on p38 MAP kinase activity
To further demonstrate the involvement of Gi-protein in the endothelin-1-activation of p38 MAP kinase we investigated the combined effects of SB203580 and pertussis toxin on [$H]arachidonic acid release and on p38 MAP kinase activity. In this experiment, CISM cells were preincubated with SB203580 and pertussis toxin, followed by endothelin-1 treatment. As shown in Figures 8(A), 8(B) and 8(C) , simultaneous blockade of Gi- 2 
activity in CISM cells
Confluent CISM cells were prelabelled with [ 3 H]arachidonic acid as described in Figure 5 . The cells were then incubated in the presence or absence of inhibitors for 15 min followed by mastoparan treatment for 10 min. [ 3 H]Arachidonic acid release into the medium was determined as described in the Materials and methods section. For determination of cPLA 2 activity, CISM cells were starved for 12 h and treated similarly as described above. PLA 2 activity in the 100 000 g cytosolic fraction was determined using L-3-phosphatidylcholine 1-stearoyl-2-[1-
14 C]arachidonyl as substrate as described in the Materials and methods section. The results are meanpS.E.M. for three determinations from one representative experiment. 
H]arachidonic acid release and cAMP formation in CISM cells
CISM cells were prelabelled with [ 3 H]arachidonic acid, then treated with 500 ng/ml pertussis toxin, 10 µM forskolin, 0.5 mM 8-bromo-cAMP, or 100 nM endothelin-1 as indicated for 1 h, 10 min, 10 min and 5 min respectively. CISM cells were either pretreated with pertussis toxin for 1 h or with forskolin for 10 min followed by treatment with endothelin-1 for 5 min. After incubation, [ 3 H]arachidonic acid release into the medium was determined as described in the Materials and methods section. For cAMP determination, CISM cells were incubated in the presence of 0.1 mM 3-isobutyl-1-methyl-xanthine for 10 min at 37 mC and cAMP in the trichloroacetic acid-soluble extract was determined by radioimmunoassay as described in the Materials and methods section. In each case, separate controls (without agonist) were incubated for a specified time and the percentage increases of [ 3 H]arachidonic acid release and cAMP formation were calculated using their respective untreated controls. Data are meanspS.E.M. for three separate experiments. protein and p38 MAP kinase activity had no additive inhibitory effect on the endothelin-1 stimulation of [$H]arachidonic acid release and p38 MAP kinase activity. Equal amounts of p38 MAP kinase were immunoprecipitated from all samples ( Figure  8D ). These results add further support to our finding that p38 kinase is regulated via Gi-proteins.
Mastoparan increases p38 MAP kinase activity and [ 3 H]arachidonic acid release
Mastoparan is a cationic peptide which selectively binds to the receptor-recognition site of pertussis toxin-sensitive α-subunits of the G-proteins Gi and Go [28, 29] . Mastoparan displays a novel mode of toxicity by acting directly on G-proteins which mimics the role played by agonist-liganded receptors. As shown in Figure 9 Effects of 
Effects of cAMP-elevating agents on p38 MAP kinase activity and [ 3 H]arachidonic acid release
Since pertussis toxin increases intracellular cAMP accumulation by inhibiting Gi-proteins, it was of interest to determine whether cAMP-elevating agents exert an effect on p38 MAP kinase activity and [$H]arachidonic acid release. CISM cells were treated p38 mitogen-activated protein kinase and cytosolic phospholipase A 2 in smooth muscle
Figure 10 Effects of cAMP-elevating agents on p38 MAP kinase activity in CISM cells
Confluent CISM cells were starved for 18 h, then incubated in the absence (None) or presence of 500 ng/ml pertussis toxin (PTX), 10 µM forskolin (FSK), 0.5 mM 8-bromo-cAMP (Br-cAMP) or 100 nM endothelin-1 (ET-1) for 1 h, 10 min, 10 min, and 5 min respectively. Alternatively, CISM cells were either pretreated with pertussis toxin for 1 h or with forskolin for 10 min followed by treatment with endothelin-1 for 5 min. The p38 MAP kinase activity was measured in the immunoprecipitates using [γ-32 P]ATP and ATF2 as substrates. The phosphorylated ATF2 was detected by SDS/PAGE and autoradiography as described in Figure 1(B) . The basal activity of p38 MAP kinase did not change with the time of incubation. Results shown are from one experiment that is representative of three separate experiments.
with pertussis toxins, forskolin or 8-bromo-cAMP (a cAMP analogue) in the absence or presence of endothelin-1 and measured for [$H]arachidonic acid release and p38 MAP kinase activity. As shown in Table 4 , pertussis toxin and forskolin increased cAMP formation by 82 and 922 % respectively. However, while pertussis toxin inhibited endothelin-1-induced [$H]-arachidonic acid release by 52 %, forskolin had little effect on the stimulated arachidonic acid release (Table 4 ). In addition, while pertussis toxin, 8-bromo-cAMP and forskolin had no significant effect on basal p38 MAP kinase activity, endothelin-1-induced p38 MAP kinase activation was partially inhibited by the toxin (Figure 10 ). In contrast, pretreatment of CISM cells with forskolin had no inhibitory effects on endothelin-1-induced p38 MAP kinase activation in these cells (Figure 10 ). These data suggest that the inhibitory effect of the pertussis toxin on endothelin-1-stimulation of p38 MAP kinase activity is not mediated by cAMP formation.
DISCUSSION
In the present work, we have investigated the role of MAP kinases in endothelin-1 stimulation of cPLA # phosphorylation and activation in CISM cells. We found that p38 MAP kinase, but not p42\p44 MAP kinases, is involved in the endothelin-1 stimulation of cPLA # phosphorylation and arachidonic acid release in these cells. Furthermore, we present evidence showing that a pertussis toxin-sensitive Gi-protein may be involved in linking the endothelin-A receptor, a G-protein-coupled receptor, to the p38 MAP kinase cascade and cPLA # in these cells. These conclusions are supported by the following findings. Both p38 MAP kinase (Figure 1 ) and p42\p44 MAP kinases [21] are present in the CISM cells and both are activated by endothelin-1. SB203580, a potent specific inhibitor of p38 MAP kinase, but not the p42\p44 MAP kinases specific inhibitor, PD98059, markedly suppressed endothelin-1-enhanced cPLA # phosphorylation (Figure 4) , cPLA # activity (Table 2 ) and arachidonic acid release ( Figure 5 ). The addition of endothelin-1 resulted in p38 MAP kinase activation ( Figure 1 ) and cPLA # phosphorylation (Figure 4 ). Endothelin-1 stimulated p38 MAP kinase activity in a time- (Figure 3 ) and concentration- (Figure 2 ) dependent manner, and these effects were mediated through the endothelin-A receptor subtype (Table 1) . In general, in smooth muscle, including the iris sphincter, endothelin-1 activates phospholipases A # , C and D, intracellular Ca# + mobilization and contraction through the endothelin-A receptor subtype [1] [2] [3] [4] [5] [6] [7] . The PKC inhibitor, RO 31-8220, had no inhibitory effect on endothelin-1-induced p38 MAP kinase activation, suggesting that endothelin-1 activation of p38 MAP kinase is independent of PKC. Pertussis toxin inhibited both endothelin-1-and mastoparan-stimulation of p38 MAP kinase activity and arachidonic acid release ( Figures  7-9) . The inhibitory effects of pertussis toxin, which stimulates cAMP accumulation by inhibiting Gi-proteins, are not mediated by cAMP formation. SB203580, but not RO 31-8220, inhibited mastoparan-stimulated [$H]arachidonic acid release and cPLA # activation ( Table 3) .
The above observations are in accord with the findings of many investigators, working with a wide variety of tissues, that multiple pathways are involved in the physiological release of arachidonic acid and prostaglandin synthesis. Previously, we have reported that PKCα plays an important role in cPLA # regulation and arachidonic acid release in endothelin-1-stimulated CISM cells [21] . Thus, it is not unreasonable to conclude that in these cells endothelin-1 activates both PKCα and p38 MAP kinase to phosphorylate and activate cPLA # . It is generally believed that an increase in intracellular Ca# + concentration and phosphorylation of cPLA # are responsible for the stimulated arachidonic acid release, and that the increase in intracellular Ca# + triggers the translocation of cPLA # to the plasma membrane [30] . There is accumulating experimental evidence which indicates that in addition to PKC, MAP kinases are involved in cPLA # phosphorylation and activation in stimulated cells (reviewed in [14] ). Concomitant phosphorylation and activation of p42\p44 MAP kinases is observed in many cells [14] . Phosphorylation by p42 MAP kinase increases the intrinsic activity of the lipase by 2-3-fold as measured in itro using phosphatidylcholine as substrate [12, 13] . Phosphorylation of Ser&!& of recombinant cPLA # by p42 MAP kinase results in an increase in its activity [31] . Vascular endothelial growth factor stimulates prostacyclin production and activation of cPLA # in endothelial cells via p42\p44 MAP kinases [32] . In contrast, in human platelets cPLA # is phosphorylated in collagenand thrombin-stimulated platelets independent of PKC and p42\p44 MAP kinases [17] . Moreover, differential activation of p42\p44 MAP kinases and cPLA # phosphorylation has also been reported in macrophages [33] and neutrophils [34] . These data suggest that a different MAP kinase may cause cPLA # phosphorylation in these cells. Thus, Kramer et al. [35] showed activation of the p38 MAP kinase in thrombin-stimulated platelets and suggested that this kinase may phosphorylate cPLA # . Phosphorylation and activation of cPLA # by p38 MAP kinase has been reported in thrombin-stimulated platelets [19] , collagen-stimulated platelets [18] and in human neutrophils treated with tumour necrosis factor-α [20] . Therefore, depending on the cell type p38 MAP kinase and\or p42\p44 MAP kinases could contribute to cPLA # phosphorylation. In the endothelin-1-stimulated CISM cells, p38 MAP kinase plays an important role in the phosphorylation and activation of cPLA # . While endothelin-1-induced cPLA # phosphorylation and arachidonic acid release are inhibited by the specific PKC inhibitor, RO 31-8220, this inhibitor has no effect on the activities of p42\p44 MAP kinases [21] or p38 MAP kinase (S. Husain and A. A. Abdel-Latif, unpublished work). Thus, stimulation of the endothelin-A receptor could lead to activation of : (a) the Gqprotein that activates phospholipase C to hydrolyse polyphosphoinositides into diacylglycerol and inositol trisphosphate, which may then activate PKCα to phosphorylate and activate cPLA # [21] , and (b) the Gi-protein, which may lead to activation of p38 MAP kinase and subsequently to phosphorylation and activation of cPLA # . There is little known about the activation of p38 MAP kinase by G-protein-coupled receptors [36] . PLA # regulation by both pertussis toxin-sensitive and -insensitive Gproteins has been reported in several cell types [37] [38] [39] [40] . In the CISM cells, pertussis toxin partially inhibited endothelin-1-stimulation of p38 MAP kinase activity and arachidonic acid release (Figure 7) , suggesting involvement of Gi-proteins in cPLA # regulation. Involvement of Gi-protein in the regulation of p38 MAP kinase is further supported by the observation that simultaneous blockade of Gi-protein and p38 MAP kinase activity has no additive inhibitory effects on the endothelin-1 stimulation of [$H]arachidonic acid release and p38 MAP kinase activity (Figure 8 ). In addition, this conclusion is further supported by the finding that pertussis toxin completely inhibited mastoparan-stimulation of p38 MAP kinase activity and arachidonic acid release (Figure 9 ), which indicates that mastoparan is acting through activation of pertussis toxin-sensitive Gi-proteins in these cells. In U937 cells, mastoparan-induced arachidonic acid release is mediated through pertussis toxin-sensitive Giproteins [39] . Mastoparan activates p38 MAP kinase via a PKCindependent pathway since RO 31-8220 had no inhibitory effect on mastoparan-stimulated [$H]arachidonic acid release and cPLA # activity (Table 3) . Mastoparan is a cationic peptide which activates Giα subunits [39] . Pertussis toxin increases cellular cAMP by inhibiting Gi-protein, thus releasing adenylate cyclase from tonic inhibition [41] . The finding that cAMP-elevating agents had no effect on endothelin-1-stimulation of p38 MAP kinase and arachidonic acid release ( Figure 10, Table 4) indicates that the inhibitory effect of pertussis toxin on endothelin-1-stimulation of p38 MAP kinase and arachidonic acid release is not mediated through cAMP but is due to inhibition of the Giprotein.
In summary, we have shown here that p38 MAP kinase plays a critical role in endothelin-1-induced cPLA # phosphorylation and arachidonic acid release in CISM cells. Our data suggest that endothelin-1 binds to the endothelin-A receptor to activate the Gi-protein which, through a series of kinases, leads to the activation of p38 MAP kinase and subsequently to phosphorylation and activation of cPLA # . Activation of cPLA # leads to the liberation of arachidonic acid from membrane phospholipids. The ability of the activated endothelin-A receptor, which is coupled to both Gq-and Gi-proteins, to recruit and activate this complex signal transduction mechanism remains to be elucidated. We are currently investigating the relationships between the endothelin-A receptor, Gi-protein, p38 MAP kinase and cPLA # phosphorylation and activation. Further studies on the mechanism of these relationships could provide important information about the functions of p38 MAP kinase in smooth muscle.
